Novel <i>PPFIA1</i>-<i>ALK</i>, <i>ALK</i>-<i>C2orf91</i>(intergenic) double-fusion responded well to alectinib in an advanced lung adenocarcinoma patient: a case report. Here, ALK is linked to lung adenocarcinoma.